Improve Human Health to Preserve Patients’ Dignity

Leading the advancement of innovative therapies in genitourinary tumors and women's health

Highlights

Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® (APL-1702) subject to certain conditions, Advancing the Global Development and Commercialization of a First-in-Class Non-Surgical Treatment for Cervical Precancerous Lesions in Europe

Products

Vesique^®(APL-1202) | Cevira^® (APL-1702)

Core Areas

Urologic Oncology

Integrated diagnosis and treatment, reinforced by strengthened leadership

Women's Health

Building a robust and tiered gynecology pipeline with game-changing products

Breast and Gynecologic Oncology

Synergizing in-house R&D and licensing to cover both early- and late-stage needs

Global Partnership

News & Updates

October 7, 2026

Asieris Pharmaceuticals Enters an Exclusive Licensing Agreement with Theramex for CEVIRA® (APL-1702) subject to certain conditions, Advancing the Global Development and Commercialization of a First-in-Class Non-Surgical Treatment for Cervical Precancerous Lesions in Europe

September 22, 2026

Asieris’ APL-2501 Completes First Patient Enrollment in Clinical Trial for Advanced Solid Tumors

August 28, 2026

Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma

August 27, 2026

Asieris Pharmaceuticals’ Portable Blue Light Flexible Cystoscope APLD-2304 Receives EU CE Mark

August 26, 2026

Asieris Received NMPA IND Approval for CLDN6/9-ADC for the Treatment of Advanced Solid Tumors

August 13, 2026

Asieris Received FDA IND Approval for CLDN6/9- ADC for the Treatment of Advanced Solid Tumors

Technology Platform